Priorix: Clinical Trials

6 completed, 2 active not recruiting. 7 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	7	Completed 5, Active not recruiting 2
Phase 2	1	Completed 1

Follow Priorix: new trials by email Literature Review of Priorix trials Research Report on Priorix

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization	Phase 3	Active not recruiting	Sanofi	580	2025-02-27	2026-02-13
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization	Phase 3	Active not recruiting	Sanofi	2360	2025-02-18	2026-04-13
Baby Vaccine Study (Sched3) DTaP/IPV/Hib vaccine, 13 valent Pneumococcal Conjugate Vaccine, Rotavirus vaccine - Infectious Diseases	Phase 2	Completed	University of Oxford	189	2015-08-01	2021-09-20
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine	Phase 3	Completed	GlaxoSmithKline	1742	2014-08-25	2021-01-07
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Rubella, Measles	Phase 3	Completed	GlaxoSmithKline	5016	2012-11-09	2019-11-25
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Cervarix, Priorix, Infanrix - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	148	2012-10-15	2020-04-10
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Priorix, M-M-R II, Varivax - Measles, Mumps	Phase 3	Completed	GlaxoSmithKline	4538	2012-10-10	2021-01-07
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Priorix, M-M-R II, Kinrix - Measles-Mumps-Rubella	Phase 3	Completed	GlaxoSmithKline	4011	2012-06-21	2019-11-25

Conditions studied

Measles (4)  ·  Mumps (4)  ·  Rubella (3)  ·  Communicable Diseases (1)  ·  Papillomavirus Infections (1)

Sponsors

GlaxoSmithKline (5)  ·  Sanofi (2)  ·  University of Oxford (1)

Countries

United States (6)  ·  Mexico (4)  ·  Puerto Rico (4)  ·  Finland (3)  ·  Estonia (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  Chile (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Honduras (1)  ·  Malaysia (1)  ·  Panama (1)  ·  Philippines (1)

Top investigators

Matthew D Snape (1)

Results publications

PMID 33109390, PMID 33428870, PMID 41276263